Although there is consensus that nitric oxide (NO) modulates tumor development, it is unsettled whether it inhibits or stimulates angiogenesis and metastatic spread. The cytostatic effect of NO lends support to the belief that it has antitumor action. However, conflicting data from non-comparable experimental systems leave unsettled the effect of NO on tumor progression. Hence, a comprehensive investigation of the effects of NO on tumor progression is needed. It requires an adequate model system that takes into account two coordinate events that cooperate to produce NO: (i) The activation of NOS2 gene expression, and (ii) The transport of adequate amounts of the NO substrate L-arginine. A highly useful tumor model system employs the polyoma middle T oncogenic transgene (PyV-mT). It elicits rapid, reproducible, multifocal metastatic mammary adenocarcinoma in 100 percent of females. Sustained and copious NO production occurs via the transcriptionally controlled inducible nitric oxide synthase (NOS2) enzyme. Transport of the sole substrate for NO production, L-arginine is mediated by specific transporters (CATs). When PyV-mT is expressed in either Nos2-/- and Cat2-/- mice, the models serve to define their individual roles in breast tumor progression. We postulate that the CAT2 arginine transporter plays a central role in the regulated production of NO via NOS2. The consequences of NO produced from NOS2 and arginine transport via CAT2, will be assessed by measuring the occurrence, growth, angiogenesis and metastasis of mammary adenocarcinoma using """"""""designer"""""""" bigenic and trigenic mice. The PyV-mT transgene is a surrogate for receptor tyrosine kinase (specifically cErbB2) and is an extremely oncogenic transgene. However, the cErbB2 transgene is a more indolent oncogene exhibiting slower tumor kinetics. Transplantation studies will determine whether the stimulatory effect of NO on mammary tumor formation is epithelial cell autonomous. Alternatively, transplant experiments will reveal if circulating and/or stromal tissues are responsible for the differences in tumor progression observed between Nos2-/- and Nos2+/+ mice. An analysis of the microvascular density will be used to measure angiogenesis and the extent of apoptosis will be assessed. The role of CAT2 mediated L-arginine transport on NO production will be assessed in tumor cell lines and in appropriate tumor bearing mice. The proposed experiments directly test the role of Nos2 and Cat2 genes on angiogenesis, tumor growth, and metastasis in this model. The mammary tumor progression exhibited by these model systems have important morphological and etiological similarities with human breast cancer development. Hence, the knowledge gained will be worthwhile since both the transport of arginine and the production of NO can be modulated by diet and/or arginine analogues that modify NOS2 activity or substrate flux.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA081376-01A1
Application #
6045408
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
2000-01-14
Project End
2003-12-31
Budget Start
2000-01-14
Budget End
2000-12-31
Support Year
1
Fiscal Year
2000
Total Cost
$269,929
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Davie, Sarah A; Maglione, Jeannie E; Manner, Cathyryne K et al. (2007) Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 16:193-201
Namba, Ruria; Young, Lawrence J T; Maglione, Jeannie E et al. (2005) Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 7:R881-9
Abbey, Craig K; Borowsky, Alexander D; McGoldrick, Erik T et al. (2004) In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A 101:11438-43
Ellies, Lesley G; Fishman, Michael; Hardison, Joy et al. (2003) Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 106:1-7
Manner, Cathyryne K; Nicholson, Benjamin; MacLeod, Carol L (2003) CAT2 arginine transporter deficiency significantly reduces iNOS-mediated NO production in astrocytes. J Neurochem 85:476-82
Rosner, Andrea; Miyoshi, Keiko; Landesman-Bollag, Esther et al. (2002) Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161:1087-97
Nicholson, Benjamin; Manner, Cathyryne K; MacLeod, Carol L (2002) Cat2 L-arginine transporter-deficient fibroblasts can sustain nitric oxide production. Nitric Oxide 7:236-43
Nicholson, B; Manner, C K; Kleeman, J et al. (2001) Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J Biol Chem 276:15881-5
Soler, C; Valdes, R; Garcia-Manteiga, J et al. (2001) Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. J Biol Chem 276:30043-9
Maglione, J E; Moghanaki, D; Young, L J et al. (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298-305